CN101116674B - Mongolian medicine for treating bone fracture - Google Patents
Mongolian medicine for treating bone fracture Download PDFInfo
- Publication number
- CN101116674B CN101116674B CN200610104067A CN200610104067A CN101116674B CN 101116674 B CN101116674 B CN 101116674B CN 200610104067 A CN200610104067 A CN 200610104067A CN 200610104067 A CN200610104067 A CN 200610104067A CN 101116674 B CN101116674 B CN 101116674B
- Authority
- CN
- China
- Prior art keywords
- mongolian medicine
- medicine
- broken bone
- flos carthami
- radix notoginseng
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 81
- 208000010392 Bone Fractures Diseases 0.000 title claims abstract description 44
- 241000897928 Echinops latifolius Species 0.000 claims abstract description 19
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 19
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 19
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 3
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 20
- 244000293323 Cosmos caudatus Species 0.000 claims description 20
- 241000628997 Flos Species 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- 239000000843 powder Substances 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000002552 dosage form Substances 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 12
- 239000008280 blood Substances 0.000 abstract description 12
- 238000002474 experimental method Methods 0.000 abstract description 8
- 208000014674 injury Diseases 0.000 abstract description 7
- 230000036407 pain Effects 0.000 abstract description 6
- 238000011160 research Methods 0.000 abstract description 4
- 208000034656 Contusions Diseases 0.000 abstract description 3
- 206010024453 Ligament sprain Diseases 0.000 abstract description 3
- 230000009519 contusion Effects 0.000 abstract description 3
- 241001465754 Metazoa Species 0.000 abstract description 2
- 230000008733 trauma Effects 0.000 abstract 3
- 206010017076 Fracture Diseases 0.000 abstract 2
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 241000208688 Eucommia Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 206010061363 Skeletal injury Diseases 0.000 description 13
- 210000000988 bone and bone Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 230000035876 healing Effects 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 5
- 208000026137 Soft tissue injury Diseases 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 208000008286 Aortic Arch Syndromes Diseases 0.000 description 3
- 102000004420 Creatine Kinase Human genes 0.000 description 3
- 108010042126 Creatine kinase Proteins 0.000 description 3
- 101710088194 Dehydrogenase Proteins 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 231100000111 LD50 Toxicity 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 2
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 2
- 208000010040 Sprains and Strains Diseases 0.000 description 2
- 208000001106 Takayasu Arteritis Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 208000026915 cervical aortic arch Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- WLYGSPLCNKYESI-RSUQVHIMSA-N Carthamin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1[C@@]1(O)C(O)=C(C(=O)\C=C\C=2C=CC(O)=CC=2)C(=O)C(\C=C\2C([C@](O)([C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(O)=C(C(=O)\C=C\C=3C=CC(O)=CC=3)C/2=O)=O)=C1O WLYGSPLCNKYESI-RSUQVHIMSA-N 0.000 description 1
- DYQVDISPPLTLLR-HJQYTNQXSA-N Carthamin Natural products CC[C@H]1O[C@H]([C@H](O)[C@@H](O)[C@@H]1O)[C@]2(O)C(=C(C=C/3C(=O)C(=C(O)[C@](O)([C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)C3=O)C(=O)C=Cc5ccc(O)cc5)C(=O)C(=C2O)C(=O)C=Cc6ccc(O)cc6)O DYQVDISPPLTLLR-HJQYTNQXSA-N 0.000 description 1
- 208000025962 Crush injury Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- QWVMSYBGKWZIIE-RDFNRINOSA-N Flavochrome Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C1OC2(C)CCCC(C)(C)C2=C1)C=CC=C(/C)C=CC3C(=CCCC3(C)C)C QWVMSYBGKWZIIE-RDFNRINOSA-N 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000146 antalgic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- QXMNTPFFZFYQAI-IMDKZJJXSA-N beta-sitosterol 3-O-beta-D-glucopyranoside Natural products CC[C@H](CC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4C[C@H](CC[C@]4(C)[C@H]3CC[C@]12C)O[C@@H]5C[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)C(C)C QXMNTPFFZFYQAI-IMDKZJJXSA-N 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- NPJICTMALKLTFW-OFUAXYCQSA-N daucosterol Chemical compound O([C@@H]1CC2=CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CC[C@@H](CC)C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O NPJICTMALKLTFW-OFUAXYCQSA-N 0.000 description 1
- QDFKFNAHVGPRBL-UHFFFAOYSA-N daucosterol Natural products CCC(CCC(C)C1CCC2C1CCC3C2(C)CC=C4CC(CCC34C)OC5OC(CO)C(O)C(O)C5O)C(C)C QDFKFNAHVGPRBL-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- QWVMSYBGKWZIIE-FZKBJVJCSA-N flavochrome Chemical compound O1C2(C)CCCC(C)(C)C2=CC1C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1C(C)=CCCC1(C)C QWVMSYBGKWZIIE-FZKBJVJCSA-N 0.000 description 1
- 229930182486 flavonoid glycoside Natural products 0.000 description 1
- 150000007955 flavonoid glycosides Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000036228 toxication Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a medicine, in particular to a Mongolian medicine for bone fracture treatment. The Mongolian medicine has proved recipes of remarkable curative effect for bone fracture; however, because of shortage of summary and research, no national novel medicine has been produced so far; a plurality of proved recipes are scattered in folk, thereby facing a lost danger. With the modern art, the present invention is made by representative raw material medicines of echinops latifolius, eucommia bark, pearl, safflower and panax notoginseng on basis of collecting and sorting out the traditional proved recipes of Mongolian medicine, thereby being known as a blue-red capsule. Through proofs of animal experiments and clinical trials, the medicine has the blood activating and silting removing effects, detumescence and acesodyne and union of fracture; the medicine has a remarkable curative effect on open traumas caused by parenchyma contusions, crush traumas, joint sprains, traumas and operations, limb fractures and multi-bone fracture. The medicine is characterized in simple use, rapid effect, low cost, wide range of application, short treatment time, little pain for patients and good treatment effect.
Description
Technical field the present invention relates to a kind of medicine, i.e. a kind of mongolian medicine of set a broken bone.
The background technology bone injury comprises wounds such as fracture, soft tissue contusion, articular sprain, is the multiple commonly encountered diseases of a class.At present, the development of the treatment technology of bone injury is very fast, and the medicine and the method for diagnosis and set a broken bone are a lot., existing bone healing technology many advanced person equipment and the cooperation of operation method under carry out, the condition of requirement and medical treatment cost are all than higher, and the time of treatment is longer, the patient is relatively more painful.By contrast, traditional Mongolian medicine's mongolian medicine but has original method and magical effect for the treatment of bone injury.Activities in production such as the people of the Mongols are engaged in for a long time and herd, hunting come off a horse or cause the probability of bone injury accident higher from high falling, have accumulated abundant bone healing experience thus, have formed valuable national cultural heritage.The method of Mongolian medicine's mongolian medicine set a broken bone is simple, and produce effects is fast, and cost is low, and treatment time is short, and the patient suffering is few, is particularly suitable for the treatment of common bone injury.But, collect arrangement and theoretical research owing to lack, Mongolian medicine's bone injury technology, particularly bone injury mongolian medicine proved recipe of many preciousnesses all is scattered among the people, under the situation that mechanism is failed to understand, accidental use.Wherein, the original broad-spectrum proved recipe that has only uses single position or sick the kind in experience, has limited the performance of drug effect.What have is incomplete in secretly handing down, changed beyond recognition.What have is not lost or is on the verge of not to be lost.This present situation has limited the development of bone injury mongolian medicine, causes the bone injury mongolian medicine to rest on always and disperses on the rough level the national new drug of set a broken bone is not arranged so far.
Summary of the invention the objective of the invention is on the basis of collecting arrangement bone injury mongolian medicine proved recipe among the people, adopt modern technologies to analyze and research, propose a kind of bone injury to be had significant curative effect, and adapt to widely, usage is simple, and produce effects is fast, cost is low, treatment time is short, and the patient suffering is few, the mongolian medicine that therapeutic effect is good.
Above-mentioned purpose is realized by following technical scheme: the mongolian medicine of developing a kind of set a broken bone, be characterized in: this mongolian medicine is to be made by following bulk drugs: Echinops latifolius 15-62 part, Cortex Eucommiae 28-76 part, Margarita 0.5-8 part, Flos Carthami 15-50 part, Radix Notoginseng 5-27 part.
The mongolian medicine of said set a broken bone, its optimization prescription is: Echinops latifolius 35-42 part, Cortex Eucommiae 48-56 part, Margarita 1-6 part, Flos Carthami 22-30 part, Radix Notoginseng 9-17 part.
The mongolian medicine of said set a broken bone, its best prescription is: 39 parts of Echinops latifoliuss, 52 parts of the Cortexs Eucommiae, 3.25 parts of Margaritas, 26 parts on Flos Carthami, 13 parts of Radix Notoginseng.
The manufacture method of the mongolian medicine of said set a broken bone is: get crude drug Echinops latifolius 15-62 part, and Cortex Eucommiae 28-76 part, Margarita 0.5-8 part, Flos Carthami 15-50 part, Radix Notoginseng 5-27 part with the broken porphyrize of above-mentioned raw materials medicated powder, incapsulates.
The manufacture method of the mongolian medicine of said set a broken bone is: Margarita, Radix Notoginseng are pulverized standby; Echinops latifolius, the Cortex Eucommiae, Flos Carthami add ethanol extraction, and filtrate recycling ethanol gets thick paste; Medicinal residues decoct with water filtration, are concentrated into the thick paste shape; Two thick pastes merge, and concentrate; Mix with fine powder.
The dosage form of the mongolian medicine of said set a broken bone can be any dosage form on the pharmaceutics.
The mongolian medicine that adopts technique scheme to make, has promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain, effects such as reunion of fractured tendons and bones, through zoopery and clinical trial certificate, all have significant curative effect for multiple bone injurys such as the open wound due to soft tissue contusion, crush injury, articular sprain, wound and the operation, limb fractures, and it is simple to have usage, produce effects is fast, cost is low, characteristics such as treatment time is short, and the patient suffering is few, and therapeutic effect is good.This medicine is called the bluish red capsule in clinical experiment, owing to obtain the favorable comment of numerous triers and hospital, had certain popularity, now according to domestic well-known expert's suggestion, declares national new drug.
The specific embodiment
The present invention is on the basis of collecting a large amount of Mongolian medicine's mongolian medicine folk remedies, and the screening through a large amount of has formed the prescription scheme.Echinops latifolius is a monarch drug in the side, mainly contains alnulin acetas, 3.16-dihydroxy alnulin-3-monoacetate, cupreol, oleanolic acid, ursolic acid, daucosterol, compositions such as new sesquiterpene." mongolian medicine " (Mongolian edition teaching material) " Chinese medicine encyclopedia " (traditional Mongolian medicine volume) record: Echinops latifolius nature and flavor hardship, rare, gentle, light, blunt, cool; Has hard bone, synthetism, heat clearing away, analgesia function.The Cortex Eucommiae, Margarita are ministerial drug; Mainly contain 14 kinds of lignanoids and lignanoid's glucoside in the Cortex Eucommiae, also contain the iridoid constituents, and composition such as eucommoil, eucommoil glucoside-I.The Cortex Eucommiae " main blood, association's day (heat), synthetism "." mongolian medicine " (Mongolian edition teaching material) carries: " Cortex Eucommiae is synthetism, strong bone, heat clearing away ".The Four-Volume Medical Code (8th century Tibetan language version medical science monumental work) carries: " Cortex Eucommiae treatment fracture, bone splits and bone heat "; " onlooker's happiness " (16th century Tibetan language version medical science monumental work) carries: " Cortex Eucommiae is synthetism, cure the wound, heat clearing away, also can treat waist and leg ache "; " Chinese medicine encyclopedia " (traditional Mongolian medicine volume) carries: " Cortex Eucommiae sweet in the mouth, little suffering, property are flat, dry, blunt, heavy, gentle, soft, heat clearing away are arranged, the effect of synthetism ".Margarita contains a large amount of calcium carbonate, and compositions such as aminoacid, taurine, ornithine have detoxifcation, cure the wound, granulation promoting and treatment effects such as " aortic arch syndromes ", and " mongolian medicine " (Mongolian edition teaching material) carries: " Margarita is concocted with milk; Control aortic arch syndrome, granulation promoting, cure the wound "." aortic arch syndrome " is the clinical name of disease of traditional Mongolian medicine, and the general reference nervous system disease can comprise fracture back local nerve blood vessel injury, Margarita with the principal drug assistance synthetism, cure the wound and granulation promoting outside, can also promote the healing of injured nerve blood vessel and the recovery of function.Flos Carthami, Radix Notoginseng make for assistant, and Flos Carthami contains carthamin (C
21H
22O
11) and Flos Carthami flavochrome (C
24H
30O
5), have the effect of removing blood stasis with potent drugs promoting blood circulation to restore menstrual flow.Radix Notoginseng contains arasaponin first (C
30H
22O
16) arasaponin second (C
23H
32O
16) and flavonoid glycoside.Have hemostasis, blood stasis dispelling, detumescence, pain relieving, antiviral, antifungal effect.Full side's five kinds of Chinese medicine is auxilliary mutually for usefulness, has promoting blood circulation to remove blood stasis, reducing swelling and alleviating pain, the function of reunion of fractured tendons and bones.It also is higher, the representative crude drug of the frequency of occurrences in the middle of the mongolian medicine proved recipe.The concocting method and the dosage form of this prescription are a lot, only lift two examples:
First kind of embodiment: get 39 parts of Echinops latifoliuss by touchstone, 52 parts of the Cortexs Eucommiae, 3.25 parts of Margaritas, 26 parts on Flos Carthami, 13 parts of Radix Notoginseng.Said medicine is pulverized porphyrize, incapsulate.
Instructions of taking: mixing in water for oral taking, each 10-15g, day clothes 3 times.
Second kind of embodiment: get crude drug Echinops latifolius 390g, Cortex Eucommiae 520g, Margarita 32.5g, Flos Carthami 260g, Radix Notoginseng 130g.Margarita, Radix Notoginseng powder are broken into fine powder, and facing-up method mix homogeneously is standby.Echinops latifolius, the Cortex Eucommiae, Flos Carthami add 12 times of amount 60% alcohol reflux three times, each 2 hours.Filter, filtrate recycling ethanol gets thick paste.Medicinal residues add 14 times of water gagings and decoct secondary, and each 1.5 hours, filter, filtrate is concentrated into the thick paste shape, and two thick pastes merge, and are concentrated into relative density 1.35 (80 ℃ of surveys).Add above-mentioned fine powder and an amount of dextrin and receive cream, 60 ℃ of oven dry are ground into fine powder, add an amount of wetting agent, and 14 mesh sieves are granulated, 60 ℃ of oven dry, and 16 mesh sieve granulate incapsulate and make 1000.
Instructions of taking: be grown up one day three times, one time 3.
The experiment situation:
One. zoopery:
1. toxicity test
(1) anxious poison test.According to the pertinent regulations of study of tcm new drug, to the median lethal dose(LD 50) (LD of bluish red capsule mouse stomach administration
50) carried out test determination, but do not measure LD
50, therefore carried out mtd test.Result: with Cmax (60%), maximum dosage-feeding (60ml/kg, dividing secondary to give in one day) 36g/Kg irritates stomach, be equivalent to crude drug amount 104g/kg, 522 times (pressing 60kg) of the daily dosage of clinical plan are equivalent to be grown up, none death of mice in seven days is put to death each internal organs of mice anatomic observation and is not found toxic reaction, and administration group and control group mice do not have any difference.
(2) long term toxication. for clinical drug safety, according to the pertinent regulations of country to new drug research, application Wistar rat will be tested medicine and will be set at high, medium and low three dosage, be respectively bluish red capsule particle 4.8g/kg, 2.4g/kg, 1.2g/kg (being equivalent to crude drug 13.9g/kg, 7.0g/kg, 3.5g/kg). press human dosage (70kg) and be capsule particle calculating in 0.06g/kg/ days, be 80 times, 40 times of the human effective dose and 20 times (press 60kg, be 70 times, 35 times and 17.5 times of human effective dose); Other establishes a matched group. and gastric infusion 90 days, 180 days and the drug withdrawal of part animal are after 10 days continuously, observe of the influence of bluish red capsule to the every physiology of rat, biochemical indicator. experimental result shows: give rat continuous oral 180 days with bluish red capsule various dose, food-intake and growth promoter (body weight gain) to rat all do not have influence. liver function and renal function are not all found the overt toxicity effect. and routine blood test, blood biochemistry, urine biochemistry and bone marrow sheet etc. be there is no obvious influence, compare no significant difference with matched group between each group.
2. pharmacodynamic experiment
(1) the bluish red capsule is to the influence of rabbit union of fracture
Cause the fracture of radius model with rabbit, use bluish red basic, normal, high three dosage of capsule (0.138g/kg, 0.276g/kg, 0.552g/kg) oral administration gavage drug treatment 38 days,, take the photograph the X-ray film histopathological examination under the same conditions in different time.Dynamic observe the fracture site callus formation, union of fracture situation and optical microscope undertissue morphological change.Observe fracture rabbit active situation, food-intake, fracture site swelling degree simultaneously.And the content of mensuration fracture site fracture resistence force, callus dry weight, serum Ca, P, alkali phosphatase, creatine phosphokinase and lactic acid dehydrogenase and serum calcitonin, Bone Gla protein and growth hormone.Experimental result shows that the bluish red capsule has dose dependent ground and promotes fracture and bone defect healing.Can alleviate fracture site swelling degree and improve symptom, promote callus formation, healing place is comparatively firm.X line and pathomorphism are quantitatively marked and the fracture resistence force index all obviously is better than model control group and positive control drug pill for traumatic injuries group (P＜0.05 or P＜0.01).The bluish red capsule also has the hemorheology of improvement, reduces whole blood viscosity, increases the effect of growth hormone content in the blood.
(2) experimentation of bluish red capsule anti-inflammatory and antalgic
Adopt rat paw edema and mice ear method to carry out the antiinflammatory experiment, adopt mice hot plate method and writhing method to carry out analgesic experiment, observe of the influence of oral bluish red capsule various dose swelling and pain.The result shows: the bluish red capsule can obviously suppress the foot swelling that carrageenin brings out, and dimethylbenzene induced mice ear swelling obviously prolongs the mice hot plate method and causes the incubation period of pain and reduce the glacial acetic acid induced mice and turn round the body number of times.Prove that each dosage bluish red capsule has anti-inflammatory and analgesic effect, effect of high dosage is more obvious.
(3) the bluish red capsule is to the influence of rat soft tissue injury
Adopt the blunt nosed ferrum pestle device of self-control, (30cm) freely falls from top to down at certain altitude, causes the non-open soft tissue injury model of rat left lower extremity.With the positive matched group of pill for traumatic injuries, be provided with the blank group simultaneously, with basic, normal, high three dosage treatment of bluish red capsule 6 days, carry out perusal and pathological tissue sxemiquantitative and observe, get the detection that blood carries out serum calcium, phosphorus, alkali phosphatase, creatine phosphokinase, lactic acid dehydrogenase and whole blood viscosity simultaneously.The result: behind the bluish red capsule for treating, perusal strike position and pathological tissue observation swelling ecchymosis disappear obviously Zao than blank group, and particularly the high dose group damage location organizes majority to recover normal.Serum Ca, P and alkali phosphatase are not had influence, the influence of creatine phosphokinase and lactic acid dehydrogenase is had reduction trend with the increase of dosage, but not statistically significant.Each dosage bluish red capsule and positive control drug pill for traumatic injuries all can obviously reduce soft tissue injury rat whole blood viscosity.Illustrate that the bluish red capsule has facilitation to the healing of soft tissue injury.
Two, clinical experiment: since 2002,, received satisfied clinical efficacy in Affiliated Hospital of National University of the Inner Mongol treatment clavicular fracture 33 examples.In the Huhehaote City, ground such as Baotou, Chifeng City, Wuhai City, Ordos City, Erenhot City, Manzhouli City, Ulan Cha Bushi, Hinggan League, cylinder Ge Le alliance, Hulunbeier City, Bayan nur city, Alashan League carried out the clinical experiment of other bone injurys respectively, all obtained curative effect preferably.
Claims (8)
1. the mongolian medicine of a set a broken bone, it is characterized in that: this mongolian medicine is to be made by following bulk drugs: Echinops latifolius 15-62 part, Cortex Eucommiae 28-76 part, Margarita 0.5-8 part, Flos Carthami 15-50 part, Radix Notoginseng 5-27 part.
2. the mongolian medicine of set a broken bone according to claim 1, it is characterized in that: this mongolian medicine is to be made by following bulk drugs: Echinops latifolius 35-42 part, Cortex Eucommiae 48-56 part, Margarita 1-6 part, Flos Carthami 22-30 part, Radix Notoginseng 9-17 part.
3. the mongolian medicine of set a broken bone according to claim 1, it is characterized in that: this mongolian medicine is to be made by following bulk drugs: 39 parts of Echinops latifoliuss, 52 parts of the Cortexs Eucommiae, 3.25 parts of Margaritas, 26 parts on Flos Carthami, 13 parts of Radix Notoginseng.
4. the mongolian medicine of set a broken bone according to claim 1, it is characterized in that: the manufacture method of the mongolian medicine of said set a broken bone is: get crude drug Echinops latifolius 15-62 part, Cortex Eucommiae 28-76 part, Margarita 0.5-8 part, Flos Carthami 15-50 part, Radix Notoginseng 5-27 part with the broken porphyrize of above-mentioned raw materials medicated powder, incapsulates.
5. the mongolian medicine of set a broken bone according to claim 1, it is characterized in that: the manufacture method of the mongolian medicine of said set a broken bone is: Margarita, Radix Notoginseng are pulverized standby; Echinops latifolius, the Cortex Eucommiae, Flos Carthami add ethanol extraction, and filtrate recycling ethanol gets thick paste; Medicinal residues decoct with water filtration, are concentrated into the thick paste shape; Two thick pastes merge, and concentrate; Mix with fine powder.
6. the mongolian medicine of set a broken bone according to claim 5, it is characterized in that: the manufacture method of the mongolian medicine of said set a broken bone is: Margarita, Radix Notoginseng powder are broken into fine powder, and facing-up method mix homogeneously is standby; Echinops latifolius, the Cortex Eucommiae, Flos Carthami add 10-14 and doubly measure the 55-65% alcohol reflux three times, and each 1.5-2.5 hour, filter, filtrate recycling ethanol gets thick paste; Medicinal residues add 10-16 times of water gaging and decoct secondary, and each 1-2 hour, filter, filtrate is concentrated into the thick paste shape, and two thick pastes merge, and are concentrated into relative density 1-1.5/80 ℃; Add above-mentioned fine powder and an amount of dextrin and receive cream, 50-65 ℃ of oven dry is ground into fine powder, adds an amount of wetting agent, granulate, and 50-65 ℃ of oven dry, granulate incapsulates.
7. the mongolian medicine of set a broken bone according to claim 1 or 5, it is characterized in that: the manufacture method of the mongolian medicine of said set a broken bone is: get crude drug Echinops latifolius 390g, Cortex Eucommiae 520g, Margarita 32.5g, Flos Carthami 260g, Radix Notoginseng 130g; Margarita, Radix Notoginseng powder are broken into fine powder, and facing-up method mix homogeneously is standby; Echinops latifolius, the Cortex Eucommiae, Flos Carthami add 12 times of amount 60% alcohol reflux three times, and each 2 hours, filter, filtrate recycling ethanol gets thick paste; Medicinal residues add 14 times of water gagings and decoct secondary, each 1.5 hours, filter, filtrate is concentrated into the thick paste shape, and two thick pastes merge, and are concentrated into 1.35/80 ℃ of relative density, add above-mentioned fine powder and an amount of dextrin and receive cream, 60 ℃ of oven dry are ground into fine powder, add an amount of wetting agent, 14 mesh sieves are granulated, 60 ℃ of oven dry, 16 mesh sieve granulate incapsulate and make 1000.
8. the mongolian medicine of set a broken bone according to claim 1, it is characterized in that: the dosage form of the mongolian medicine of said set a broken bone is any dosage form on the pharmaceutics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610104067A CN101116674B (en) | 2006-08-02 | 2006-08-02 | Mongolian medicine for treating bone fracture |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610104067A CN101116674B (en) | 2006-08-02 | 2006-08-02 | Mongolian medicine for treating bone fracture |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101116674A CN101116674A (en) | 2008-02-06 |
| CN101116674B true CN101116674B (en) | 2010-05-12 |
Family
ID=39053028
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610104067A Active CN101116674B (en) | 2006-08-02 | 2006-08-02 | Mongolian medicine for treating bone fracture |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101116674B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105596410A (en) * | 2016-01-15 | 2016-05-25 | 内蒙古民族大学附属医院 | Mongolian medicine for treating bone fracture |
| CN109394824A (en) * | 2018-12-20 | 2019-03-01 | 内蒙古民族大学附属医院 | A kind of anaesthetic of bone-setting pain stopping and preparation method thereof |
| CN110269878A (en) * | 2019-07-12 | 2019-09-24 | 通辽市蒙医整骨医院 | A kind of mongolian medicine of set a broken bone, soft tissue injury |
| CN112461981B (en) * | 2020-11-25 | 2023-02-03 | 内蒙古医科大学 | Mongolian medicine Tabusson-2 extraction process response surface optimization method and detection method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095600A (en) * | 1992-11-26 | 1994-11-30 | 王璐林 | Bone regeneration pill |
-
2006
- 2006-08-02 CN CN200610104067A patent/CN101116674B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1095600A (en) * | 1992-11-26 | 1994-11-30 | 王璐林 | Bone regeneration pill |
Non-Patent Citations (1)
| Title |
|---|
| 奥.乌力吉等.蒙医传统手法结合蒙药治疗锁骨骨折33例.第四届全国民族医药学术论文交流暨《中国民族医药杂志》创刊10周庆典大会论文集.2005,(10),54. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101116674A (en) | 2008-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102091202B (en) | Traditional Chinese medicinal composition for treating fracture and preparation method thereof | |
| CN103845348A (en) | Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating dysmenorrhea | |
| CN101116674B (en) | Mongolian medicine for treating bone fracture | |
| CN110478452A (en) | A kind of Chinese medicine composition and preparation method thereof for treating gout | |
| CN104524247B (en) | One treats migrainous medical composition and its use | |
| CN103027978A (en) | Medicine composition for treating traumatic injury and preparation method of medicine composition | |
| CN1695682A (en) | External use preparation for treating rheumatisma and bone injuries | |
| CN100411661C (en) | Amber bolus | |
| CN102670740B (en) | Drug composition for treating soft tissue injuries and preparation process thereof | |
| CN101698037B (en) | Medicine for treating uterine bleeding and preparation process thereof | |
| CN101322771A (en) | Capsules for treating gynecology inflammation | |
| CN101703649B (en) | Chinese patent medicament for treating bone traumatism and preparation process thereof | |
| CN1931300A (en) | Externally applied medicine for treating women's dysmenorrhea | |
| CN102302636A (en) | Medicament for treating burn and preparation method thereof | |
| CN102961662B (en) | Medicine for treating gastric ulcer and preparation method thereof | |
| CN107412536A (en) | A kind of external preparation of three high drop and preparation method thereof | |
| CN115154504B (en) | Traditional Chinese medicine composition for treating yang deficiency and blood stasis type gonarthritis as well as preparation method and application thereof | |
| CN1718218A (en) | Medicine for treating osteoarthritis, and its prepn. method | |
| CN104306708A (en) | Medicine for treating spleen deficiency type menstrual period irregularity and application thereof | |
| CN111214552A (en) | Pharmaceutical composition and application thereof | |
| CN105726849B (en) | It is a kind of for treating the Chinese medicine of diabetes Depression | |
| CN104107226A (en) | Compound bone-joining tablet | |
| CN104001077A (en) | Traditional Chinese medicine composition for treating urinary tract infection and application thereof | |
| WO2022082485A1 (en) | Traditional chinese medicine compound composition having multiple effects and application thereof in pharmaceutical preparation | |
| CN113144056A (en) | A Chinese medicinal composition for improving intelligence |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HU NAN HANSEN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: AO WULIJI Effective date: 20110504 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 028000 SCHOOL OF MONGOLIAN MEDICINE, INNER MONGOLIA UNIVERSITY FOR THE NATIONALITIES, NO. 16, HUOLINHE STREET, TONGLIAO CITY, INNER MONGOLIA AUTONOMOUS REGION TO: 413002 YINCHENG SOUTH ROAD, YIYANG CITY, HU NAN PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110504 Address after: Yiyang City, Hunan Province Silver City Road 413002 Patentee after: Hunan Hansen Pharmaceutical Co.,Ltd. Address before: School of medicine Inner Mongolia University for the Nationalities No. 16 the Inner Mongolia Autonomous Region 028000 Tongliao City Huolinhe Street Patentee before: Ao Wuliji |